S. 545 · 119th Congress (2025–2027)
Combating Illicit Xylazine Act
This bill regulates xylazine under the Controlled Substances Act (CSA).
Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.
This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.
Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.
The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.
The bill also exempts xylazine manufacturers from the CSA's physical security requirements.
Finally, the bill requires the DEA, in coordination with the Department of Health and Human Services (HHS), to provide Congress with a report on how the agencies previously determined whether xylazine should be a controlled substance, including the full text of HHS's recommendations to the DEA for scheduling xylazine.
Show official title
A bill to prohibit certain uses of xylazine, and for other purposes.
Reported
This bill’s path
This is S. 545’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
- Sponsor
- Sen. Catherine Cortez Masto (D-NV)
- Cosponsors
35 cosponsors
18 original · 17 later
19 R · 15 D · 1 I
- Sen. Richard Blumenthal (D-CT)· Original · Feb 12, 2025
- Sen. Katie Boyd Britt (R-AL)· Original · Feb 12, 2025
- Sen. Maria Cantwell (D-WA)· Original · Feb 12, 2025
- Sen. Shelley Moore Capito (R-WV)· Original · Feb 12, 2025
- Sen. Chuck Grassley (R-IA)· Original · Feb 12, 2025
- Sen. Kirsten E. Gillibrand (D-NY)· Original · Feb 12, 2025
- Sen. Margaret Wood Hassan (D-NH)· Original · Feb 12, 2025
- Sen. Cindy Hyde-Smith (R-MS)· Original · Feb 12, 2025
- Sen. Amy Klobuchar (D-MN)· Original · Feb 12, 2025
- Sen. Mark Kelly (D-AZ)· Original · Feb 12, 2025
- Sen. Tim Kaine (D-VA)· Original · Feb 12, 2025
- Sen. Ben Ray Luján (D-NM)· Original · Feb 12, 2025
- Sen. James E. Risch (R-ID)· Original · Feb 12, 2025
- Sen. Jacky Rosen (D-NV)· Original · Feb 12, 2025
- Sen. Jeanne Shaheen (D-NH)· Original · Feb 12, 2025
- Sen. Rick Scott (R-FL)· Original · Feb 12, 2025
- Sen. Roger F. Wicker (R-MS)· Original · Feb 12, 2025
- Sen. Todd Young (R-IN)· Original · Feb 12, 2025
- Sen. Ruben Gallego (D-AZ)· Later · Feb 18, 2025
- Sen. Thom Tillis (R-NC)· Later · Feb 24, 2025
- Sen. John Fetterman (D-PA)· Later · Jul 16, 2025
- Sen. Michael F. Bennet (D-CO)· Later · Jul 22, 2025
- Sen. Ted Budd (R-NC)· Later · Jul 23, 2025
- Sen. Cynthia M. Lummis (R-WY)· Later · Jul 23, 2025
- Sen. Angus S. King Jr. (I-ME)· Later · Jul 24, 2025
- Sen. James C. Justice (R-WV)· Later · Sep 10, 2025
- Sen. Mike Crapo (R-ID)· Later · Sep 29, 2025
- Sen. David McCormick (R-PA)· Later · Feb 10, 2026
- Sen. James Lankford (R-OK)· Later · Feb 24, 2026
- Sen. Ashley Moody (R-FL)· Later · Mar 17, 2026
- Sen. Marsha Blackburn (R-TN)· Later · Mar 19, 2026
- Sen. John Cornyn (R-TX)· Later · Mar 19, 2026
- Sen. Ted Cruz (R-TX)· Later · Mar 26, 2026
- Sen. Richard J. Durbin (D-IL)· Later · Mar 26, 2026
- Sen. Jeff Merkley (D-OR)· Later · Jun 9, 2026
- Policy area
- Crime and Law Enforcement
- Subjects
- Congressional oversight
- Consumer affairs
- Criminal procedure and sentencing
- Drug safety, medical device, and laboratory regulation
- Drug trafficking and controlled substances
- Licensing and registrations
- Manufacturing
- U.S. Sentencing Commission
1 more
- Veterinary medicine and animal diseases
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Feb 12, 2025 – Apr 15, 2026
Referred to committee
Read twice and referred to the Committee on the Judiciary.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Sources
- Congress.gov action
- Senate
Committees
Mar 26, 2026 · Meeting
Mar 19, 2026 · Meeting
Mar 12, 2026 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
Combating Illicit Xylazine Act
Display title, Short title · Reported to Senate, Introduced in Senate
A bill to prohibit certain uses of xylazine, and for other purposes.
Official title · Introduced in Senate